Fruquintinib plus chemo for HER2-negative gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding fruquintinib (a targeted drug that blocks blood vessel growth) to chemotherapy after surgery for HER2-negative stomach or gastroesophageal junction cancer. It is for patients whose tumor did not respond well to previous treatment before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that is HER2-negative (a protein test).
- Your tumor did not shrink much after chemo before surgery (TRG 2 or 3).
- You had successful surgery to remove all visible cancer (R0 resection).
- You are in good general health (able to do daily activities) and expected to live at least 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests a combination of chemotherapy, immunotherapy, and a targeted drug called fruquintinib for people with stomach cancer. It is for two groups: those who can have surgery after treatment (neoadjuvant therapy) and those whose cancer is advanced or spread to limited areas (conversion therapy).
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.